Compare
Gevo, Inc. vs Aemetis, Inc vs Codexis, Inc. vs Alto Ingredients, Inc.
| Latest fiscal year | Gevo, Inc. GEVO | Aemetis, Inc AMTX | Codexis, Inc. CDXS | Alto Ingredients, Inc. ALTO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $160.58M | $197.63M | $70.39M | $917.93M |
| Revenue growth (YoY) | +849.3% | -26.2% | +18.6% | -4.9% |
| Gross margin | n/a | -0.4% | 86.7% (computed) | 3.8% |
| Operating margin | -12.6% | -18.8% | -59.3% | 0.8% |
| Net margin | -21.1% | -39.0% | -62.5% | 1.5% |
| Net income | -$33.84M | -$77.00M | -$43.97M | $13.34M |
| EPS (Diluted) | -$0.14 | -$1.28 | -$0.50 | $0.16 |
| Operating cash flow | -$13.40M | $3.26M | -$19.38M | $13.24M |
| Free cash flow | -$43.51M | -$22.74M | -$23.85M | $8.65M |
| Cash & equivalents | $81.16M | $4.89M | $50.79M | $23.41M |
| Total assets | $718.93M | $259.84M | $147.80M | $388.79M |
| Total liabilities | $247.76M | n/a | $97.27M | $143.54M |
| Shareholders' equity | $466.34M | -$306.83M | $50.53M | $245.24M |
| Return on year-end equity | -7.3% | n/a | -87.0% | 5.4% |
| Shares outstanding | 242.46M | 66.19M | 90.48M | 77.31M |
Revenue, most recent five fiscal years
| Fiscal year | Gevo, Inc. | Aemetis, Inc | Codexis, Inc. | Alto Ingredients, Inc. |
|---|---|---|---|---|
| Latest | $160.58M Ended 2025-12-31 | $197.63M Ended 2025-12-31 | $70.39M Ended 2025-12-31 | $917.93M Ended 2025-12-31 |
| 1 year earlier | $16.91M Ended 2024-12-31 | $267.64M Ended 2024-12-31 | $59.34M Ended 2024-12-31 | $965.26M Ended 2024-12-31 |
| 2 years earlier | $17.20M Ended 2023-12-31 | $186.72M Ended 2023-12-31 | $70.14M Ended 2023-12-31 | $1.22B Ended 2023-12-31 |
| 3 years earlier | $1.18M Ended 2022-12-31 | $256.51M Ended 2022-12-31 | $138.59M Ended 2022-12-31 | $1.34B Ended 2022-12-31 |
| 4 years earlier | $533.0K Ended 2021-12-31 | $211.95M Ended 2021-12-31 | $104.75M Ended 2021-12-31 | $1.21B Ended 2021-12-31 |